Abstract
Background Heart Failure (HF)-related mortality has been showing an upward trend since 2012. In this study, we assessed nationwide trends in mortality related to HF among women and focused on women 15-55 years of age in the United States from 1999 to 2020.
Methods Trends in mortality related to HF were assessed through a cross-sectional analysis of the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiological Research database. Age-adjusted mortality rates per 1,000,000 people and associated annual percent changes with 95% Confidence Intervals(CI) were determined. Joinpoint regression was used to assess the trends in the overall, demographic (sex, race and ethnicity, age), and regional groups.
Results Between 1999 and 2020, 1,035,383 women died of heart failure. The age-adjusted mortality rate remained stable from 1999-2005, saw a reduction till 2012 and then an increase till 2020. Higher mortality rates were observed for Black patients, and patients ≥55 years of age. Large metropolitan counties had lesser mortality burden compared to rural counterparts. In 15-55 age group,18,875 women died due to heart failure.The discrepancy in mortality rates was even more pronounced between races in 15-55 age group.
Conclusions Following an initial period of stability, HF-related mortality in women worsened from 2012 to 2020 in the United States. Black women had higher AAMR compared with White women, with a significant geographic variation. In the premenopausal group, black women had 4 times worse AAMR compared to their white counterparts. Focus towards preventative medicine, early diagnosis, and bridging the disparities, including socioeconomic, to promote healthcare equality should be upheld.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective observational study was exempt from local institutional review board review. The study uses deidentified government-issued public use data set and follows the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
mohamed.eid{at}rochesterregional.org, keerthi.renjith{at}rochesterregional.org, ncordeiro{at}maimonidesmed.org, hazel.lever{at}rochesterregional.org, Jeffrey_Alexis{at}urmc.rochester.edu, sabu_thomas{at}urmc.rochester.edu
Data Availability
The study uses deidentified government-issued public use data set and follows the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting.
